Business Context and Reporting Period
This Form 8-K was filed by RXi Pharmaceuticals Corporation (also referred to as Phio Pharmaceuticals Corp.) on November 4, 2015. The report addresses a regulatory event concerning the company's listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on compliance with Nasdaq listing rules regarding stock price.
Material Changes
The primary material event is the company's failure to regain compliance with Nasdaq Listing Rule 5550(a)(2) by the initial deadline of November 3, 2015. The company's common stock had closed below the minimum $1.00 per share requirement for 30 consecutive business days prior to the initial notification on May 7, 2015.
Guidance, Outlook, and Management Commentary
- Extension Granted: Nasdaq granted the company an additional 180-day compliance period, extending until May 2, 2016, to regain compliance.
- Compliance Criteria: To maintain listing, the stock must achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during this new period.
- Management Strategy: Management intends to monitor the stock price and may implement a reverse stock split if necessary to cure the deficiency.
- Other Requirements: The company met all other applicable requirements for initial listing, including the market value of publicly held shares.
Investor Verification Checklist
- Verify the current trading price of RXi Pharmaceuticals common stock to assess proximity to the $1.00 threshold.
- Monitor future filings for announcements regarding the implementation of a reverse stock split.
- Confirm the company's ability to maintain the 10 consecutive days of compliance before the May 2, 2016 deadline.
- Review the company's cash position to ensure it can fund operations while addressing the listing deficiency.